0.80Open0.80Pre Close0 Volume3 Open Interest7.50Strike Price0.00Turnover187.40%IV25.06%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type-0.2653Delta0.0842Gamma11.18Leverage Ratio-0.0323Theta-0.0016Rho-2.96Eff Leverage0.0068Vega
Relay Therapeutics Stock Discussion
they just needed a catalyst from rate cuts and this expectation is enough to tr...
rate cut by fed is needed as a key catalyst
Relay Therapeutics Announces Clinical Trial Collaboration With Pfizer to Evaluate Atirmociclib in Combination With Rly-2608
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Oppenheimer strategist John Stoltzfus has outlined 10 predictions for the transformative impact of generative AI across various industries. The key focus of generative AI lies in its revolutionary potential to create entirely novel designs and products that may surpass human imagination.
1. Healthcare Augm...
this stock got a whole discount sale rn, put in while its low and u gon make some REAL bread
No comment yet